RxDoctor Payments Data

Dorothy Min, MD

Nephrology · Hainesport, NJNPI 1518915131

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $15,500 of the $16,287 with a category attached, or 95.2%. Aurinia Pharma U.S., Inc. accounts for 96.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $9,142 and has fallen 99.5% since, to $43 in 2025. Among nephrology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,287in general payments, 2019–2025

Across 24 payments — averaging $678.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aurinia Pharma U.S., Inc.$16K
  • AbbVie$201
  • Amgen$137
  • AstraZeneca$108
  • Vifor Pharma, Inc.$33
  • Mallinckrodt Hospital Products Inc.$23
  • plus $20 from 1 others

What the payments were for

  • Speaking & faculty fees$15,50095%
  • Food & beverage$7875%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,287 in reported general payments places this provider in the 95th percentile of 413 nephrology providers in New Jersey.

See all nephrology providers in New Jersey

Medicare billing

Part B allowed, 2024
$295,204
Medicare patients
553
Services billed
8,588

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin92$104,606
FarxigaDapagliflozin Propanediol113$97,557
KerendiaFinerenone31$24,759
LokelmaSodium Zirconium Cyclosilicate16$24,427
EliquisApixaban15$18,029
Telmisartan-AmlodipineTelmisartan/Amlodipine52$16,957
Sevelamer Carbonate91$14,443
SpsSodium Polystyrene Sulfon/Sorb16$10,252
Clonidine28$6,094
Telmisartan157$4,741
Cinacalcet Hcl16$4,240
Calcium Acetate37$3,157
Potassium Citrate ErPotassium Citrate16$2,719
Nifedipine ErNifedipine53$2,092
Midodrine Hcl20$2,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$108$121,984129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 413 nephrology providers in New Jersey.

Other nephrology in Hainesport

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →